To evaluate the impact of NF-κB activity on the leukemic phenotype of T-ALL, Vilimas et al. [67] treated human T-ALL cell lines with NF-κB canonical pathway inhibitors. Here, NFKB1 is linked to acute lymphoblastic leukemia.